Drug discovery in the ubiquitin - Proteasome system

Nature Reviews Drug Discovery

Volumn 5, Issue 7, 2006, Pages 596-613

  Nalepa, Grzegorz ^a,b   Rolfe, Mark ^c   Harper, J Wade ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 BIS(5 HYDROXYMETHYL 2 THIENYL)FURAN; ANTIINFLAMMATORY AGENT; BCR ABL PROTEIN; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; BORTEZOMIB; FURAN DERIVATIVE; HEAT SHOCK PROTEIN 90 INHIBITOR; I KAPPA B; IMATINIB; IMIDAZOLINE DERIVATIVE; LIGASE INHIBITOR; NEDD8 PROTEIN; NUTLINS; PARKIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN E6; PROTEIN INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN MDM2; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON HIPPEL LINDAU PROTEIN; WART VIRUS VACCINE; ZINC FINGER PROTEIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; GENETIC TRANSCRIPTION; GLIOMA; GROWTH INHIBITION; HAPPY PUPPET SYNDROME; HUMAN; INHIBITION KINETICS; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OVARY CANCER; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN METABOLISM; PROTEIN PROCESSING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; WART VIRUS;

ANIMALS; DRUG DESIGN; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

EID: 33745674468     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2056     Document Type: Article

References (169)

1. Pickart, C. M. Back to the future with ubiquitin. Cell 116, 181-190 (2004).
2. Wilkinson, K. D. Ubiquitin: A Nobel protein. Cell 119, 741-745 (2004).
3. Hershko, A., Ciechanover, A. & Varshavsky, A. Basic Medical Research Award. The ubiquitin system. Nature Med. 6, 1073-1081 (2000).
4. Ang, X. L. & Harper, J. W. Interwoven ubiquitination oscillators and control of cell cycle transitions. Sci. STKE pe31 (2004).
5. Moberg, K. H., Bell, D. W., Wahrer, D. C., Haber, D. A. & Hariharan, I. K. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 413, 311-316 (2001).
6. Koh, M. S., Ittmann, M., Kadmon, D., Thompson, T. C. & Leach, F. S. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol. Ther. 5, 78-83 (2006).
7. Ruffner, H., Joazeiro, C. A., Hemmati, D., Hunter, T. & Verma, I. M. Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl Acad. Sci. USA 98, 5134-5139 (2001).
8. Ekholm-Reed, S. et al. Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res. 64, 795-800 (2004).
9. Gandhi, S. & Wood, N. W. Molecular pathogenesis of Parkinson's disease. Hum. Mol. Genet. 14 (Spec. No. 2), 2749-2755 (2005).
10. Gasser, T. Genetics of Parkinson's disease. Curr. Opin. Neurol. 18, 363-369 (2005).
11. Dauer, W. & Przedborski, S. Parkinson's disease: Mechanisms and models. Neuron 39, 889-909 (2003).
12. Vila, M. & Przedborski, S. Genetic clues to the pathogenesis of Parkinson's disease. Nature Med. 10 (Suppl.), S58-S62 (2004).
13. Tanaka, K., Suzuki, T., Hattori, N. & Mizuno, Y. Ubiquitin, proteasome and parkin. Biochim. Biophys. Acta 1695, 235-247 (2004).
14. Al-Kuraya, K. et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 64, 8534-8540 (2004).
15. Honda, R., Tanaka, H. & Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27 (1997).
16. Iwakuma, T. & Lozano, G. MDM2, an introduction. Mol. Cancer Res. 1, 993-1000 (2003).
17. Nakayama, T. et al. MDM2 gene amplification in bone and soft-tissue tumors: Association with tumor progression in differentiated adipose-tissue tumors. Int. J. Cancer 64, 342-346 (1995).
18. Shieh, S. Y., Ikeda, M., Taya, Y. & Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334 (1997).
19. Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996).
20. Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206 (1995).
21. Li, M. et al. Mono- versus polyubiquitination: Differential control of p53 fate by Mdm2. Science 302, 1972-1975 (2003).
22. Carrano, A. C., Eytan, E., Hershko, A. & Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biol. 1, 193-199 (1999).
23. Hershko, D. et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 91, 1745-1751 (2001).
24. Kossatz, U. et al. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev. 18, 2602-2607 (2004).
25. Nakayama, K. et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J. 19, 2069-2081 (2000).
26. Nakayama, K. et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev. Cell 6, 661-672 (2004).
27. Nijman, S. M. et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773-786 (2005).
28. Rubinfeld, B. et al. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 275, 1790-1792 (1997).
29. Welcker, M. et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl Acad. Sci. USA 101, 9085-9090 (2004).
30. Wei, W., Jin, J., Schlisio, S., Harper, J. W. & Kaelin, W. G. Jr. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 25-33 (2005).
31. Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417-421 (2004).
32. Burger, A. M. & Seth, A. K. The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications. Eur. J. Cancer 40, 2217-2229 (2004).
33. Orlowski, R. Z. et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420-4427 (2002).
34. Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617 (2003).
35. Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498 (2005).
36. Nalepa, G. & Wade Harper, J. Therapeutic anti-cancer targets upstream of the proteasome. Cancer Treat. Rev. 29 (Suppl. 1), 49-57 (2003).
37. Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 351, 1860-1873 (2004).
38. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503-533 (2001).
39. Hershko, A., Heller, H., Elias, S. & Ciechanover, A. Components of ubiquitin-protein ligase system. Resolution, affinity purification & role in protein breakdown. J. Biol. Chem. 258, 8206-8214 (1983).
40. Ciechanover, A., Elias, S., Heller, H. & Hershko, A. 'Covalent affinity' purification of ubiquitin-activating enzyme. J. Biol. Chem. 257, 2537-2542 (1982).
41. Ciechanover, A., Elias, S., Heller, H., Ferber, S. & Hershko, A. Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. J. Biol. Chem. 255, 7525-7528 (1980).
42. Ciechanover, A., Heller, H., Elias, S., Haas, A. L. & Hershko, A. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc. Natl Acad. Sci. USA 77, 1365-1368 (1980).
43. Vijay-Kumar, S., Bugg, C. E. & Cook, W. J. Structure of ubiquitin refined at 1. 8 A resolution. J. Mol. Biol. 194, 531-544 (1987).
44. Chau, V. et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243, 1576-1583 (1989).
45. Gregori, L., Poosch, M. S., Cousins, G. & Chau, V. A uniform isopeptide-linked multiubiquitin chain is sufficient to target substrate for degradation in ubiquitin-mediated proteolysis. J. Biol. Chem. 265, 8354-8357 (1990).
46. Pickart, C. M. Ubiquitin in chains. Trends Biochem. Sci. 25, 544-548 (2000).
47. Huang, D. T. et al. A unique E1-E2 interaction required for optimal conjugation of the ubiquitin-like protein NEDD8. Nature Struct. Mol. Biol. 11, 927-935 (2004).
48. Huang, D. T. et al. Structural basis for recruitment of Ubc12 by an E2 binding domain in NEDD8's E1. Mol. Cell 17, 341-350 (2005).
49. Lois, L. M. & Lima, C. D. Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1. EMBO J. 24, 439-451 (2005).
50. VanDemark, A. P. & Hill, C. P. E1 on the move. Mol. Cell 17, 474-475 (2005).
51. Ren, R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Rev. Cancer 5, 172-183 (2005).
52. Arkin, M. R. & Wells, J. A. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nature Rev. Drug Discov. 3, 301-317 (2004).
53. Jones, D., Crowe, E., Stevens, T. A. & Candido, E. P. Functional and phylogenetic analysis of the ubiquitylation system in Caenorhabditis elegans: Ubiquitin-conjugating enzymes, ubiquitin-activating enzymes & ubiquitin-like proteins. Genome Biol. 3, 2.1-2.15 (2002).
54. Stickle, N. H. et al. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol. Cell Biol. 24, 3251-3261 (2004).
55. Harper, J. W. Neddylating the guardian; Mdm2 catalyzed conjugation of Nedd8 to p53. Cell 118, 2-4 (2004).
56. Xirodimas, D. P., Saville, M. K., Bourdon, J. C., Hay, R. T. & Lane, D. P. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118, 83-97 (2004).
57. Hatakeyama, S., Yada, M., Matsumoto, M., Ishida, N. & Nakayama, K. I. U box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 276, 33111-33120 (2001).
58. Zheng, N. et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416, 703-709 (2002).
59. Huang, L. et al. Structure of an E6AP-UbcH7 complex: Insights into ubiquitination by the E2-E3 enzyme cascade. Science 286, 1321-1326 (1999).
60. Petroski, M. D. & Deshaies, R. J. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol. Cell Biol. 6, 9-20 (2005).
61. Fang, S., Lorick, K. L., Jensen, J. P. & Weissman, A. M. RING finger ubiquitin protein ligases: Implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin. Cancer Biol. 13, 5-14 (2003).
62. Lane, D. P. & Lain, S. Therapeutic exploitation of the p53 pathway. Trends Mol. Med. 8, S38-S42 (2002).
63. Balint, E. E. & Vousden, K. H. Activation and activities of the p53 tumour suppressor protein. Br. J. Cancer 85, 1813-1823 (2001).
64. Pavletich, N. P., Chambers, K. A. & Pabo, C. O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7, 2556-2564 (1993).
65. Vousden, K. H. & Prives, C. P53 and prognosis: New insights and further complexity. Cell 120, 7-10 (2005).
66. Vousden, K. H. & Lu, X. Live or let die: The cell's response to p53. Nature Rev. Cancer 2, 594-604 (2002).
67. Zhang, Z. et al. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279, 16000-16006 (2004).
68. Wang, H., Nan, L., Yu, D., Agrawal, S. & Zhang, R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res. 7, 3613-3624 (2001).
69. Prasad, G., Wang, H., Agrawal, S. & Zhang, R. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res. 22, 107-116 (2002).
70. Zhang, R., Wang, H. & Agrawal, S. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: Proof of principle, in vitro and in vivo activities & mechanisms. Curr. Cancer Drug Targets 5, 43-49 (2005).
71. Karlsson, G. B. et al. Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: Visualisation of reporter gene induction at the single-cell level. Br. J. Cancer 91, 1488-1494 (2004).
72. Bottger, A. et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7, 860-869 (1997).
73. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
74. Rubinstein, L. V. et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl Cancer Inst. 82, 1113-1118 (1990).
75. Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nature Med. 10, 1321-1328 (2004).
76. Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606 (1997).
77. Sakaguchi, K. et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12, 2831-2841 (1998).
78. Grossman, S. R. et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300, 342-344 (2003).
79. Zhu, Q., Yao, J., Wani, G., Wani, M. A. & Wani, A. A. Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: Evidence for the role of p300 in integrating ubiquitination and proteolysis. J. Biol. Chem. 276, 29695-29701 (2001).
80. Krajewski, M., Ozdowy, P., D'Silva, L., Rothweiler, U. & Holak, T. A. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nature Med. 11, 1135-1136 (2005).
81. Grinkevich, V., Issaeva, N., Hossain, S., Pramanik, A. & Selivanova, G. Reply to 'NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro'. Nature Med. 11, 1136-1137 (2005).
82. Lasne, C., Lowy, R. & Venegas, W. In vitro induction of sister-chromatid exchanges after G0 exposure of human lymphocytes to five naphthofurans. Mutagenesis 4, 27-30 (1989).
83. Touati, E., Krin, E., Quillardet, P. & Hofnung, M. 7-Methoxy-2-nitronaphtho[2,1-b]furan (R7000)-induced mutation spectrum in the lacI gene of Escherichia coli: Influence of SOS mutagenesis. Carcinogenesis 17, 2543-2550 (1996).
84. Quillardet, P., Boscus, D., Touati, E. & Hofnung, M. DNA damage induced in vivo by 7-methoxy-2-nitronaphtho[2,1-b]-furan (R7000) in the lacI gene of Escherichia coli. Mutat. Res. 422, 237-245 (1998).
85. Quillardet, P., Michel, V., Arrault, X., Hofnung, M. & Touati, E. Mutagenic properties of a nitrofuran, 7-methoxy-2-nitronaphtho[2,1-b]furan (R7000), in lacI transgenic mice. Mutat. Res. 470, 177-188 (2000).
86. Bossy-Wetzel, E., Schwarzenbacher, R. & Lipton, S. A. Molecular pathways to neurodegeneration. Nature Med. 10 (Suppl.), S2-S9 (2004).
87. Dawson, T. M. & Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822 (2003).
88. Farrer, M. J. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nature Rev. Genet. 7, 306-318 (2006).
89. Giasson, B. I. & Lee, V. M. Are ubiquitination pathways central to Parkinson's disease? Cell 114, 1-8 (2003).
90. Kahle, P. J. & Haass, C. How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep. 5, 681-685 (2004).
91. Nutt, J. G. & Wooten, G. F. Clinical practice. Diagnosis and initial management of Parkinson's disease. N. Engl. J. Med. 353, 1021-1027 (2005).
92. Tolosa, E., Wenning, G. & Poewe, W. The diagnosis of Parkinson's disease. Lancet Neurol. 5, 75-86 (2006).
93. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
94. Pesah, Y. et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131, 2183-2194 (2004).
95. Greene, J. C., Whitworth, A. J., Andrews, L. A., Parker, T. J. & Pallanck, L. J. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum. Mol. Genet. 14, 799-811 (2005).
96. Haywood, A. F. & Staveley, B. E. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci. 5, 14 (2004).
97. Yamada, M., Mizuno, Y. & Mochizuki, H. Parkin gene therapy for α-synucleinopathy: A rat model of Parkinson's disease. Hum. Gene Ther. 16, 262-270 (2005).
98. Shimura, H. et al. Ubiquitination of a new form of α-synuclein by parkin from human brain: Implications for Parkinson's disease. Science 293, 263-269 (2001).
99. Ang, X. L. & Wade Harper, J. (2001). SCF-mediated protein degradation and cell cycle control. Oncogene 24, 2860-2870 (2001).
100. Jin, J. et al. (2001). Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 18, 2573-2580 (2001).
101. Latres, E., Chiaur, D. S. & Pagano, M. (2001). The human F box protein β-Trcp associates with the Cul1/Skp1 complex and regulates the stability of β-catenin. Oncogene 18, 849-854 (2001).
102. Wu, G. et al. Structure of a β-TrCP1-Skp1-β-catenin complex: destruction motif binding and lysine specificity of the SCF(β-TrCP1) ubiquitin ligase. Mol. Cell 11, 1445-1456 (2003).
103. Read, M. A. et al. Nedd8 modification of cul-1 activates SCF(β(TrCP))-dependent ubiquitination of IκBα. Mol. Cell Biol. 20, 2326-2333 (2000).
104. Fero, M. L. et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis & female sterility in p27(Kip1)-deficient mice. Cell 85, 733-744 (1996).
105. Kiyokawa, H. et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85, 721-732 (1996).
106. Nakayama, K. et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia & pituitary tumors. Cell 85, 707-720 (1996).
107. Bhattacharya, S. et al. SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells. Oncogene 22, 2443-2451 (2003).
108. Tedesco, D., Lukas, J. & Reed, S. I. The pRb-related protein p130 is regulated by phosphorylationdependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes Dev. 16, 2946-2957 (2002).
109. Bornstein, G. et al. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J. Biol. Chem. 278, 25752-25757 (2003).
110. Kamura, T. et al. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc. Natl Acad. Sci. USA 100, 10231-10236 (2003).
111. Dehan, E. & Pagano, M. Skp2, the FoxO1 hunter. Cancer Cell 7, 209-210 (2005).
112. Huang, H. et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl Acad. Sci. USA 102, 1649-1654 (2005).
113. Gstaiger, M. et al. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl Acad. Sci. USA 98, 5043-5048 (2001).
114. Shim, E. H. et al. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia & low-grade carcinoma in the mouse prostate. Cancer Res. 63, 1583-1588 (2003).
115. Piva, R. et al. In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. Mol. Cell Biol. 22, 8375-8387 (2002).
116. Sumimoto, H. et al. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther. 12, 95-100 (2005).
117. Kudo, Y. et al. Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol. Cancer Ther. 4, 471-476 (2005).
118. Jiang, F., Caraway, N. P., Li, R. & Katz, R. L. RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells. Oncogene 24, 3409-3418 (2005).
119. Katagiri, Y., Hozumi, Y. & Kondo, S. Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J. Dermatol Sci. 42, 215-224 (2006).
120. Hao, B. et al. Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase. Mol. Cell 20, 9-19 (2005).
121. Winston, J. T. et al. The SCFβ-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev. 13, 270-283 (1999).
122. Rajagopalan, H. et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 428, 77-81 (2004).
123. Hemann, M. T. et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436, 807-811 (2005).
124. Kim, W. & Kaelin, W. G., Jr. The von Hippel-Lindau tumor suppressor protein: New insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13, 55-60 (2003).
125. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999).
126. Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nature Cell Biol. 2, 423-427 (2000).
127. Stebbins, C. E., Kaelin, W. G., Jr. & Pavletich, N. P. Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function. Science 284, 455-461 (1999).
128. Hon, W. C. et al. Structural basis for the recognition of hydroxyproline in HIF-1 α by pVHL. Nature 417, 975-978 (2002).
129. Isaacs, J. S. et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 α-degradative pathway. J. Biol. Chem. 277, 29936-29944 (2002).
130. Isaacs, J. S., Xu, W. & Neckers, L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3, 213-217 (2003).
131. Aravind, L. & Koonin, E. V. The U box is a modified RING finger- a common domain in ubiquitination. Curr. Biol. 10, R132-R134 (2000).
132. Ohi, M. D., Vander Kooi, C. W., Rosenberg, J. A., Chazin, W. J. & Gould, K. L. (2003). Structural insights into the U-box, a domain associated with multiubiquitination. Nature Struct. Biol. 10, 250-255.
133. Hatakeyama, S. & Nakayama, K. I. U-box proteins as a new family of ubiquitin ligases. Biochem. Biophys. Res. Commun. 302, 635-645 (2003).
134. Xu, W. et al. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl Acad. Sci. USA 99, 12847-12852 (2002).
135. Zhou, P. et al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J. Biol. Chem. 278, 13829-13837 (2003).
136. Meacham, G. C., Patterson, C., Zhang, W., Younger, J. M. & Cyr, D. M. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nature Cell Biol. 3, 100-105 (2001).
137. Imai, Y. et al. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease & enhances its ubiquitin ligase activity. Mol. Cell 10, 55-67 (2002).
138. Huibregtse, J. M., Scheffner, M., Beaudenon, S. & Howley, P. M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl Acad. Sci. USA 92, 2563-2567 (1995).
139. Anglesio, M. S. et al. Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum. Mol. Genet. 13, 2061-2074 (2004).
140. Talis, A. L., Huibregtse, J. M. & Howley, P. M. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV -positive and HPV-negative cells. J. Biol. Chem. 273, 6439-6445 (1998).
141. Cooper, E. M., Hudson, A. W., Amos, J., Wagstaff, J. & Howley, P. M. Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein. J. Biol. Chem. 279, 41208-41217 (2004).
142. Kishino, T., Lalande, M. & Wagstaff, J. UBE3A/E6-AP mutations cause Angelman syndrome. Nature Genet. 15, 70-73 (1997).
143. Verdecia, M. A. et al. Conformational flexibility underlies ubiquitin ligation mediated by the WWP1 HECT domain E3 ligase. Mol. Cell 11, 249-259 (2003).
144. Scheffner, M., Huibregtse, J. M., Vierstra, R. D. & Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505 (1993).
145. Huibregtse, J. M., Scheffner, M. & Howley, P. M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 10, 4129-4135 (1991).
146. Rolfe, M. et al. Reconstitution of p53-ubiquitinylation reactions from purified components: The role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP). Proc. Natl Acad. Sci. USA 92, 3264-3268 (1995).
147. Gross-Mesilaty, S. et al. Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc. Natl Acad. Sci. USA 95, 8058-8063 (1998).
148. Gewin, L., Myers, H., Kiyono, T. & Galloway, D. A. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/ E6-AP complex. Genes Dev. 18, 2269-2282 (2004).
149. Matsuura, T. et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nature Genet. 15, 74-77 (1997).
150. Buntinx, I. M. et al. Clinical profile of Angelman syndrome at different ages. Am. J. Med. Genet. 56, 176-183 (1995).
151. Duensing, S. & Munger, K. Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins. Int. J. Cancer 109, 157-162 (2004).
152. Kim, Y., Cairns, M. J., Marouga, R. & Sun, L. Q. E6AP gene suppression and characterization with in vitro selected hammerhead ribozymes. Cancer Gene Ther. 10, 707-716 (2003).
153. Foster, S. A. & Phelps, W. C. Zn(2+) fingers and cervical cancer. J. Natl Cancer Inst. 91, 1180-1181 (1999).
154. Harper, D. M. et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367, 1247-1255 (2006).
155. Mayeaux, E. J., Jr. Harnessing the power of prevention: Human papillomavirus vaccines. Curr. Opin. Obstet. Gynecol. 18 (Suppl. 1), S15-S21 (2006).
156. Lowy, D. R. & Schiller, J. T. Prophylactic human papillomavirus vaccines. J. Clin. Invest. 116, 1167-1173 (2006).
157. Sakamoto, K. M. et al. Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554-8559 (2001).
158. Sakamoto, K. M. et al. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol. Cell Proteomics 2, 1350-1358 (2003).
159. Zhou, P., Bogacki, R., McReynolds, L. & Howley, P. M. Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol. Cell 6, 751-756 (2000).
160. Verma, R. et al. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 298, 611-615 (2002).
161. Goldenberg, S. J. et al. Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell 119, 517-528 (2004).
162. Zheng, J. et al. CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol. Cell 10, 1519-1526 (2002).
163. Cope, G. A. & Deshaies, R. J. COP9 signalosome: A multifunctional regulator of SCF and other cullin-based ubiquitin ligases. Cell 114, 663-671 (2003).
164. Wei, N. & Deng, X. W. The COP9 signalosome. Annu. Rev. Cell Dev. Biol. 19, 261-286 (2003).
165. Ambroggio, X. I., Rees, D. C. & Deshaies, R. J. JAMM: A metalloprotease-like zinc site in the proteasome and signalosome. PLoS Biol. 2, E2 (2004).
166. Cope, G. A. et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 298, 608-611 (2002).
167. Verma, R., Oania, R., Graumann, J. & Deshaies, R. J. Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin - proteasome system. Cell 118, 99-110 (2004).
168. Verma, R. et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 306, 117-120 (2004).
169. Schwartz, D. C. & Hochstrasser, M. (2003). A superfamily of protein tags: Ubiquitin, SUMO and related modifiers. Trends Biochem. Sci. 28, 321-328.